This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Torres-Rodríguez, J. M.
Right arrow Articles by Lagunas, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Torres-Rodríguez, J. M.
Right arrow Articles by Lagunas, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1999, p. 1258-1259, Vol. 43, No. 5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Susceptibilities of Clinical Yeast Isolates to the New Antifungal Eberconazole Compared with Their Susceptibilities to Clotrimazole and Ketoconazole

Josep M. Torres-Rodríguez,1,* Raúl Mendez,1 Olga López-Jodra,1 Yolanda Morera,1 Mateu Espasa,1 Teresa Jimenez,1 and Carme Lagunas2

Experimental and Clinical Mycology Research Group (GREMEC), IMIM, Autonomous University of Barcelona,1 and Department of Microbiology, Laboratories Salvat,2 Barcelona, Spain

Received 17 September 1998/Returned for modification 20 October 1998/Accepted 1 March 1999

The antifungal activity of eberconazole, a new imidazole derivative, against 124 clinical isolates of Candida comprising eight different species and to 34 isolates of Cryptococcus neoformans was compared to those of clotrimazole and ketoconazole. MICs of eberconazole, determined by the National Committee for Clinical Laboratory Standards standardized microbroth method, were equal to or lower than those of other azoles, especially for Candida krusei and Candida glabrata, which are usually resistant to triazoles.

* Corresponding author. Mailing address: Experimental and Clinical Mycology Research Group, IMIM, Autonomous University of Barcelona, Avda. Dr. Aiguader 80, Barcelona 08003, Spain. Phone: 34-93-221-1009. Fax: 34-93-221-3237. E-mail: jmtorres{at}imim.es.

Antimicrobial Agents and Chemotherapy, May 1999, p. 1258-1259, Vol. 43, No. 5
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Fernandez-Torres, B., Inza, I., Guarro, J. (2005). Evaluation of Disk Diffusion Method for Determining Eberconazole Susceptibility of Dermatophytes and Influence of Culture Medium. Antimicrob. Agents Chemother. 49: 2116-2118 [Abstract] [Full Text]  
  • Fernandez-Torres, B., Inza, I., Guarro, J. (2003). In Vitro Activities of the New Antifungal Drug Eberconazole and Three Other Topical Agents against 200 Strains of Dermatophytes. J. Clin. Microbiol. 41: 5209-5211 [Abstract] [Full Text]  
  • Rambali, B., Fernandez, J. A., Van Nuffel, L., Woestenborghs, F., Baert, L., Massart, D. L., Odds, F. C. (2001). Susceptibility testing of pathogenic fungi with itraconazole: a process analysis of test variables. J Antimicrob Chemother 48: 163-177 [Abstract] [Full Text]  
  • Pelletier, R., Peter, J., Antin, C., Gonzalez, C., Wood, L., Walsh, T. J. (2000). Emergence of Resistance of Candida albicans to Clotrimazole in Human Immunodeficiency Virus-Infected Children: In Vitro and Clinical Correlations. J. Clin. Microbiol. 38: 1563-1568 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»